Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.

Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK.

Med Pediatr Oncol. 2001 Jan;36(1):194-6.

PMID:
11464881
2.

Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.

Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK.

Clin Cancer Res. 1998 Sep;4(9):2135-9.

3.

N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.

Cheung NK, Kushner BH, LaQuaglia M, Kramer K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, Larson SM, Wuest D, Byrnes M, Dantis E, Mora J, Cheung IY, Rosenfield N, Abramson S, O'Reilly RJ.

Med Pediatr Oncol. 2001 Jan;36(1):227-30.

PMID:
11464891
4.
6.

3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study.

Cheung NK, Kushner BH, Yeh SJ, Larson SM.

Prog Clin Biol Res. 1994;385:319-28. No abstract available.

PMID:
7972227
7.

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.

Cheung NK, Kushner BH, Cheung IY, Kramer K, Canete A, Gerald W, Bonilla MA, Finn R, Yeh SJ, Larson SM.

J Clin Oncol. 1998 Sep;16(9):3053-60.

PMID:
9738575
8.
9.

Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.

Kushner BH, Modak S, Basu EM, Roberts SS, Kramer K, Cheung NK.

Cancer. 2013 Aug 1;119(15):2789-95. doi: 10.1002/cncr.28137.

10.
11.

Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.

Cheung NK, Landmeier B, Neely J, Nelson AD, Abramowsky C, Ellery S, Adams RB, Miraldi F.

J Natl Cancer Inst. 1986 Sep;77(3):739-45.

PMID:
3091900
12.
13.

Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.

Cheung NK, Cheung IY, Canete A, Yeh SJ, Kushner B, Bonilla MA, Heller G, Larson SM.

Cancer Res. 1994 Apr 15;54(8):2228-33.

14.

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S.

J Clin Oncol. 2012 Sep 10;30(26):3264-70. doi: 10.1200/JCO.2011.41.3807.

15.

Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.

Cheung NK, Canete A, Cheung IY, Ye JN, Liu C.

Int J Cancer. 1993 May 28;54(3):499-505.

PMID:
8509225
16.

Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.

Kushner BH, Kramer K, Modak S, Cheung NK.

J Clin Oncol. 2011 Mar 20;29(9):1168-74. doi: 10.1200/JCO.2010.28.3317.

17.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK.

Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.

18.

Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

Cheung NK, Ostrovnaya I, Kuk D, Cheung IY.

J Clin Oncol. 2015 Mar 1;33(7):755-63. doi: 10.1200/JCO.2014.57.6777.

19.

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.

Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD, Wolden SL, Larson SM, Cheung NK.

J Clin Oncol. 2007 Dec 1;25(34):5465-70.

PMID:
18048828
20.

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA.

Clin Cancer Res. 2004 Oct 15;10(20):6985-92.

Supplemental Content

Support Center